Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 66 publications.

Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D. Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S35. doi: 10.1016/j.jval.2024.03.184

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Michel A, Latocha M, Schmidt-Ott UM, Lovic N, Brunck LR, Johnson KT, Suzart-Woischnik K. Evaluation of physician knowledge of safety and safe use information for intravitreal aflibercept injection in Europe: a second survey of physicians following dissemination of updated risk-minimization materials. Pharmaceut Med. 2024 Jan;38(1):63-73. doi: 10.1007/s40290-023-00506-7

Stothers Rosenberg S, Ng X, Mansfield C, Poulos C, Peay H, Lee TH, Irony T, Ho M. Adaptation of the WOMAC for use in a patient preference study. Ther Innov Regul Sci. 2023 Jul;57(4):702-11. doi: 10.1007/s43441-023-00510-8

Poulos C, Ng X, Mansfield C, Rosenberg S, Peay H, Lee J, Irony T, Ho M. Logical soundness in a discrete choice experiment study of benefit risk preferences. Presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Sarda SP, Heyes A, Bektas M, Thankur T, Chao W, Intorcia M, Wronski S, Jones DL. Humanistic and economic burden of geographic atrophy: a systematic literature review. Clin Opththa. 2021 Dec 8;2021(15):4629-44.

Ng X, Stothers S, Mansfield C, Poulos C, Peay H, Lee TS, Irony T, Ho M. Adaptation of the Western Ontario McMaster Universities (WOMAC) osteoarthritis index for use in a patient preference study to inform regulatory decision-making. Poster presented at the 2021 SMDM Virtual Annual Meeting; October 19, 2021.

Kupperman BD, Keyloun KR, Campbell JH, Zhou X, Davenport E, Bakri SJ. Decreased vision improvement in DME eyes with longer duration or larger amounts of excess edema: a post-hoc analysis of protocol T. Presented at the 2021 54th Retina Society Annual Scientific Meeting; September 29, 2021. Chicago, IL.

Jones DL, Bektas M, Heyes A, Wronski S, Sarda SP. Clinical & humanistic burden of geographic atrophy (GA). Poster presented at the 2021 EURETINA Virtual Congress; September 9, 2021.

Ho M, Gonzalez JM, Mansfield C, Wilson L. Three preference studies sponsored by FDA CBER to inform benefit-risk assessment for biologics. Presented at the Virtual ISPOR 2021 Conference; May 20, 2021.

Samuelson TW, Singh IP, Williamson BK, Falvey H, Lee WC, Odom D, McSorley D, Katz LJ. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021 Mar 15;229:220-9. doi: 10.1016/j.ajo.2021.03.007

Zografos L, Rivero-Ferrer E, Abramsky S, Lou J, Davenport E, Wolin D. Evaluation of the physician education component of the ozurdex risk management plan. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Gonzalez Sepulveda JM, Irony T, Mansfield C, Wilson L. Stated preferences to inform benefit-risk assessment for biologics-three FDA-sponsored studies. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020.

Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport E, Hollis KA, Djokanovic N, Racanelli VS, Petraro P, Vassilev ZP. Evaluation of physician knowledge of the key safety information for aflibercept in Canada: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):235-46. doi: 10.1007/s40290-019-00278-z

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):219-33. doi: 10.1007/s40290-019-00279-y

Chambers TM, Agopian AJ, Lewis RA, Langlois PH, Danysh HE, Weber KA, Shaw GM, Mitchell LE, Lupo PJ. Epidemiology of anophthalmia and microphthalmia: prevalence and patterns in Texas, 1999-2009. Am J Med Genet A. 2018 Sep;176(9):1810-8. doi: 10.1002/ajmg.a.40352

Margulis AV, Houben E, Hallas J, Overbeek JA, Pottegard A, Torp-Pedersen T, Perez-Gutthann S, Arana A. Ophthalmic nepafenac use in the Netherlands and Denmark. Acta Ophthalmol. 2017 Aug;95(5):509-17. doi: 10.1111/aos.13468

Herring W, Carrico J, Mladsi D, Pierson RF, Lofland JH. A review of vision-related utility values and their suitability for use in cost-effectiveness models in age-related macular degeneration. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A159.

Park J, Covert D, Fairchild C, Brubaker M, Martin SA, Lewis S, DeMuro C. Development of an eye drop comfort measure for topical ocular drop application. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A364.

Margulis A, Houben E, Olesen M, Hallas J, Overbeek J, Pottegard A, Ye W, Villegas D, Perez-Gutthann S, Arana A. Drug utilization study: evaluation of the use of nepafenac in the Netherlands and Denmark. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):225.

Herring W, Mladsi DM. External validation of health economic models for complex chronic diseases: lessons from a population model for diabetic retinopathy. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A88.

Yuan BG, Tham VM, Browne EN, Weinrib R, Borkar DS, Parker JV, Uchida A, Vinoya AC, Acharya NR. Association between smoking and uveitis: results from the Pacific Ocular Inflammation study. Ophthalmology. 2015 Jun;122(6):1257-61. doi: 10.1016/j.ophtha.2015.02.03

Herring WL, Grant TJ, Mladsi DM. A mathematical model to estimate the health benefits and costs of diabetic retinopathy screening programs. Presented at the 2015 Institute for Operations Research and Management Science Computing Conference; January 12, 2015. Richmond, VA.

Rathinam SR, Babu M, Thundikandy R, Kanakath A, Nardone N, Esterberg E, Lee SM, Enanoria WT, Porco TC, Browne EN, Weinrib R, Acharya NR. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014 Oct;121(10):1863-70. doi: 10.1016/j.ophtha.2014.04.023

Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222

Borkar DS, Gonzales JA, Tham VM, Esterberg E, Vinoya AC, Parker JV, Uchida A, Acharya NR. Association between atopy and herpetic eye disease: results from the pacific ocular inflammation study. JAMA Ophthalmol. 2014 Mar;132(3):326-31. doi: 10.1001/jamaophthalmol.2013.6277

Mascarenhas J, Lalitha P, Prajna NV, Srinivasan M, Das M, D'Silva SS, Oldenburg CE, Borkar DS, Esterberg EJ, Lietman TM, Keenan JD. Acanthamoeba, fungal, and bacterial keratitis: a comparison of risk factors and clinical features. Am J Ophthalmol. 2014 Jan;157(1):56-62. doi: 10.1016/j.ajo.2013.08.032

Pearson I, Rycroft C, Irving A, Ainsworth C, Wittrup-Jensen K. A systematic literature review of utility weights in wet age-related macular degeneration. J Med Econ. 2013 Nov;16(11):1307-16.

Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV, Vinoya AC, Uchida A. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol. 2013 Nov;131(11):1405-12. doi: 10.1001/jamaophthalmol.2013.4237

Ray M, Goldstein S, Zhou S, Potamousis K, Sarkar D, Newton MA, Esterberg E, Kendziorski C, Bogler O, Schwartz DC. Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. BMC genomics. 2013 Jul 26;14:505. doi: 10.1186/1471-2164-14-505

Fortuny J, Leteneux-Pantias C, Xu X, Plana E. Prevalence and incidence of pathologic myopia and retinal neovascularization in a US managed care database. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, United States. [abstract] Value Health. 2013 May; 16(3):A176.

Borkar DS, Tham VM, Esterberg E, Ray KJ, Vinoya AC, Parker JV, Uchida A, Acharya NR. Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study. Ophthalmology. 2013 Mar;120(3):451-6. doi: 10.1016/j.ophtha.2012.09.007

See CW, Srinivasan M, Saravanan S, Oldenburg CE, Esterberg EJ, Ray KJ, Glaser TS, Tu EY, Zegans ME, McLeod SD, Acharya NR, Lietman TM. Prior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial. Ophthalmic Epidemiol. 2012 Dec;19(6):407-13.

Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect. 2012 Mar;2(1):21-8. doi: 10.1007/s12348-011-0047-5

Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.

Qian Y, Glaser T, Esterberg E, Acharya NR. Depression and visual functioning in patients with ocular inflammatory disease. Am J Ophthalmol. 2012 Feb;153(2):370-378.e. doi: 10.1016/j.ajo.2011.06.028

Oldenburg CE, Sy A, Srinivasan M, Toutain-Kidd CM, Mascarenhas J, Ravindran M, Rajaraman R, Esterberg EJ, Chidambaram JD, Acharya NR, Lietman TM, Zegans ME. Pre-existing blindness in a cohort of patients with bacterial keratitis. Br J Ophthalmol. 2011 Dec;95(11):1612-3. doi: 10.1136/bjophthalmol-2011-300270.

Oldenburg CE, Keenan JD, Cevallos V, Chan MF, Acharya NR, Gaynor BD, McLeod SD, Esterberg EJ, Porco TC, Lietman TM. Microbiological cure times in acanthamoeba keratitis. Eye (Lond). 2011 Sep;25(9):1155-60. doi: 10.1038/eye.2011.126

Rahman MQ, Abeysinghe SS, Kelly S, Roskell NS, Shannon PR, Abdlseaed AA, Montgomery DMI. Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database. Br J Ophthalmol. 2011 Jul 1;95(7):966-70.

Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, Fortuny J. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010 Jul;26(7):1587-97. doi: 10.1185/03007995.2010.482503 PMID 20429823

Arana A, Arellano FM, Rivero E, Pavesi M, Dey D, Wentworth CW. Intravitreal (IVT) injection-related ocular adverse events in the general population of the United States of America. Poster presented at the 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2008. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2008 Aug; 17(Suppl 1):S75-6.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AR. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul 1;11(4):563-74.

Arana A, Arellano FM, Rivero E, Parvesi M, Dey D, Wentworth CE. Intravitreal (IVT) injectionrelated ocular adverse events in the general population of the United States of America. Presented at the 24th International Conference on Pharmacoepidemiology; 2008.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics. 2007 Oct 1;25(10):863-79.

Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007 Sep 1;29(9):2096-106.

Wolowacz SE. Economic analysis of macugen for age-related macular degeneration. Poster presented at the Royal College of Surgeons; February 2, 2007. London, England.

Javitt JC, Wolowacz SE, Roskell NS, Maciver F, Kelly S, Pleil AM, Zlateva GP. Cost-effectiveness of pegaptanib in age-related macular degeneration: the impact of differences between USA and UK health care systems. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.

Wolowacz SE, Roskell NS, Maciver F, Kelly S. Cost-utility analysis for pegaptanib in age-related macular degeneration in the UK: the impact of demographic and disease characteristics. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.

Rubino A, Davis KL, Wang J, Rousculp MD, Tzivelekis S, Girach A. Prevalence of diagnosed diabetic retinopathy and its severity in four European countries. Poster presented at the 42nd Annual Meeting of the European Association for the Study of Diabetes; September 17, 2006. Previously presented at the 66th Scientific Session of the American Diabetes Association.

Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.